Federal contract award
75F40120F19036
FIRM FIXED PRICE AWARD PIPELINE ASSESSMENT FOR PHARMACODYNAMIC BIOMARKERS IN BIOSIMILAR DEVELOPMENT FDA THREE-WAY-MATCHING INVOICE CLAUSE-COR: ROBERTJ.PARKER@FDA.HHS.GOV
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541611 — Administrative Management and General Management Consulting Services |
| PSC | R499 — Other Professional Services |
| Parent award / vehicle | HHSF223201510027B |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $409.7K |
| Current contract value | $409.7K |
| Potential contract value / ceiling | $409.7K |
| Start date | Jul 26, 2020 |
| Current end date | Mar 15, 2021 |
| Potential end date | Sep 15, 2021 |
| Latest award activity | Feb 23, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Feb 23, 2026 | P00002 | $0 | FIRM FIXED PRICE AWARD PIPELINE ASSESSMENT FOR PHARMACODYNAMIC BIOMARKERS IN BIOSIMILAR DEVELOPMENT FDA THREE-WAY-MATCHING INVOICE CLAUSE-COR: ROBERTJ.PARKER@FDA.HHS.GOV THE PURPOSE OF THIS MODIFICATION IS TO REVISE THE STATEMENT OF WORK IN ACCO |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.